Immune Homeostasis in Sepsis and Septic Shock (IMHOTEP)

Charles University, Czech Republic

Status: Enrolling

Conditions: Immunologic Paralysis; Immunologic Suppression; Immune Deficiency; Sepsis

Treatments: Other: transcriptomics; Other: cytokines; Other: flow-cytometry

Study type: Observational

Funder types: Other

Identifiers

NCT04448951

IMHOTEP

Details and patient eligibility

About

Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• sepsis/septic shock (SEPSIS-3)
• age ≥18
• informed consent
• inclusion within first 24hrs after development/diagnosis of septic shock

Exclusion criteria

• disagreement of the patient or legal representative with the entry into the study
• patients with primary or secondary immunodeficiency
• presence of active haematological malignancy or an active non-haematological malignancy

Trial design

200 participants in 3 patient groups

sepsis/septic shock

Description:

target population

Treatment:

Other: flow-cytometry

Other: cytokines

Other: transcriptomics

non-septic critically ill

Description:

demographically-matched control group

Treatment:

Other: flow-cytometry

Other: cytokines

Other: transcriptomics

healthy control

Description:

control group

Treatment:

Other: flow-cytometry

Other: cytokines

Other: transcriptomics